Is there a Role for Bevacizumab in Non-Glial Tumors?

Author(s): Elisa Trevisan, Luca Bertero, Michela Magistrello, Roberta Ruda, Riccardo Soffietti

Journal Name: Current Drug Targets

Volume 16 , Issue 7 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Angiogenesis is one of the hallmarks of cancer, including brain tumors. The vascular endothelial growth factor (VEGF) family and their receptors are of utmost importance in the complex interaction between pro- and anti-angiogenic factors, and have a crucial role in tumor angiogenesis. Up to date, targeting the VEGF pathway with specific drugs has yielded interesting results in oncology. In particular bevacizumab (Bev), a humanized monoclonal antibody against VEGF-A, has been approved by the Food and Drug Administration (FDA) for use in recurrent glioblastomas failing standard radiochemotherapy. Bevacizumab is now being extensively investigated in several non-glial brain tumors, such as vestibular schwannomas, meningiomas, ependymomas, medulloblastomas and miscellaneous histotypes. The aim of this review is to reevaluate the literature on the use of Bev in non-glial brain tumors.

Keywords: Bevacizumab, brain tumors, ependymomas, medulloblastomas, meningiomas, vestibular schwannomas, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 27 July, 2015
Page: [684 - 688]
Pages: 5
DOI: 10.2174/1389450116666150325230810
Price: $65

Article Metrics

PDF: 27